PTCT NASDAQ
PTC Therapeutics, Inc.
1W: -0.8%
1M: -2.5%
3M: -19.0%
YTD: -20.4%
1Y: -8.6%
3Y: +159.1%
5Y: +63.4%
$62.09
+1.02 (+1.67%)
After Hours: $62.49 (+0.40, +0.65%)
Weekly Expected Move ±5.7%
$54
$57
$61
$64
$68
Credit Risk of going bust: lower than 68% of companies Debt: 12.0% of company value Bonds: $48.8M held by 18 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.66 (down 99%), PTC Therapeutics, Inc. would be worth roughly what it owes.
Total debt $696.5M against a stock market value of $5.10B.
Distance to default 7.29 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $323.2M (short-term plus half of long-term), stock volatility 40.6%; Altman Z'' 1.03. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.66 (down 99%), PTC Therapeutics, Inc. would be worth roughly what it owes.
Total debt $696.5M against a stock market value of $5.10B.
Distance to default 7.29 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $323.2M (short-term plus half of long-term), stock volatility 40.6%; Altman Z'' 1.03. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-05-27
Earliest Filing
2025-12-29
Latest Filing
partner: 10
investor: 2
target: 1
Counterparties (Filed by PTCT)
13 relationshipsCompanies named in PTCT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Royalty Pharma Investments 2019 ICAV | RPRX | investor | Purchased 100% of the Company's retained interest in sales-based royalty payments from Roche's Evrysdi product for $240 | 2025-12-29 | View |
| Royalty Pharma plc | RPRX | partner | Named as a party to the Amendment regarding the sale of royalty interests. | 2025-12-29 | View |
| Censa Pharmaceuticals, Inc. | — | target | Former target of the Company in a 2020 Merger Agreement; subject of Rights Satisfaction Agreement regarding cancellation | 2025-08-07 | View |
| Hydro Merger Sub, Inc. | — | partner | Delaware corporation party to the 2020 Merger Agreement alongside the Company and Censa. | 2025-08-07 | View |
| Shareholder Representative Services LLC | — | partner | Colorado LLC acting as representative, agent, and attorney-in-fact for the securityholders of Censa. | 2025-08-07 | View |
| Warren CC Acquisitions, LLC | — | partner | Landlord entering into a First Amendment to Lease Agreement with the Company. | 2025-01-03 | View |
| Novartis Pharmaceuticals Corporation | NVSEF | partner | License and Collaboration Agreement for PTC518 Huntington's disease program | 2024-12-02 | View |
| Royalty Pharma Investments 2019 ICAV | RPRX | investor | Purchased 38.0447% of PTC's retained royalty rights in Evrysdi for $1.0 billion | 2023-10-19 | View |
| Royalty Pharma plc | RPRX | partner | Named party in the amended royalty purchase agreement | 2023-10-19 | View |
| F. Hoffman-La Roche Ltd. | — | partner | Original licensee and collaborator under the Evrysdi License Agreement | 2023-10-19 | View |
| Hoffman-La Roche Inc. | — | partner | Original licensee and collaborator under the Evrysdi License Agreement | 2023-10-19 | View |
| Spinal Muscular Atrophy Foundation | — | partner | Collaborator in the SMA program under the original License Agreement | 2023-10-19 | View |
| Warren CC Acquisitions, LLC | — | partner | Landlord in a lease agreement for office and laboratory space. | 2022-05-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-28 | Material Agreement | Agreement | View |
| 2026-08-13 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-30 | Earnings Release; Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-18 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-06-16 | Other Events; Exhibits | View | |
| 2026-06-09 | Officer/Director Change; Exhibits | View | |
| 2026-06-05 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-28 | Regulation FD; Exhibits | View | |
| 2026-03-25 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-02-19 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-29 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-11-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-19 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-07 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-07-28 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR